JASCADE (Preferential PDE4 Inhibitor) Comprehensive Clinical and Therapeutic Guide and Trial Data

Overview of JASCADE and Novel Mechanism of Action

  • Target and Uniqueness: JASCADE is characterized by a novel mechanism of action that differentiates it from previous treatments in the therapeutic area. It specifically addresses three key areas in patient pathology:

    • Anti-inflammatory Effect: Targeting the inflammatory pathways that drive disease progression.

    • Anti-fibrotic Effect: Addressing the continuous deposition of scar tissue.

    • Vascular Properties: Focusing on the endothelial barrier to protect against and reduce the frequency of vascular leaks.

  • Preferential Inhibition of PDE4B:

    • JASCADE is a preferential inhibitor of the Phosphodiesterase 4 (PDE4PDE4) enzyme, specifically exhibiting a 99-fold preferential inhibition of the PDE4BPDE4B isoenzyme.

    • This specificity distinguishes it from "pan-PDE4PDE4" inhibitors, which are often limited by significant gastrointestinal (GIGI) side effects (referred to as "baggage").

    • Biochemical Mechanism: By inhibiting PDE4BPDE4B, the drug increases levels of Cyclic Adenosine Monophosphate (CAMPCAMP or cyclic AMPAMP).

    • Physiological Impact: Regular PDE4BPDE4B activity typically reduces CAMPCAMP levels; JASCADE intervention preserves CAMPCAMP, thereby mitigating inflammation, fibrosis (scar tissue laying down), and the degradation of the vascular endothelial layer.

The FibroNir ILD Clinical Trial Design

  • Trial Overview: The primary evidence for JASCADE's efficacy comes from the FibroNir ILD trial.

  • Duration: The study was 52 weeks52\,\text{weeks} in length.

  • Patient Population: The trial included 1178 patients1178\,\text{patients}, which is considered a large cohort for a rare disease study.

  • Randomization: Patients were randomized in a 1:1:11:1:1 ratio into three groups:

    • Placebo group.

    • JASCADE 9 mg9\,mg group.

    • JASCADE 18 mg18\,mg group.

  • Background Therapy: Patients were permitted to participate with or without background anti-fibrotic treatment (e.g., OFEVOFEV).

  • Primary Endpoint: The absolute change from baseline in Forced Vital Capacity (FVCFVC) at 52 weeks52\,\text{weeks}, comparing the placebo group to the JASCADE groups.

  • Key Secondary Endpoints: A composite endpoint measuring the time to the first occurrence of:

    1. First hospitalization for a respiratory cause.

    2. Death.

    3. ILD (Interstitial Lung Disease) exacerbations.

  • Statistical Note on Composite Endpoints: For a composite endpoint to meet its primary goal in certain contexts, all components must typically be hit, or the overall composite must reach statistical significance.

Inclusion and Exclusion Criteria

  • Inclusion Demographics: The trial included younger patients (minimum age of 18 years18\,\text{years}) with specific lung function values and confirmed diagnoses for progressing disease.

  • Mycophenolate Mofetil (MMFMMF/CellCept) Exclusion:

    • Patients using MMFMMF were initially excluded from the study.

    • Rationale: The goal was to ensure that the observed treatment effect was attributable to JASCADE alone, rather than a cohesive effect where MMFMMF was performing the primary work.

    • Proviso: After a period of 6 months6\,\text{months}, if a patient’s underlying disease showed worsening, investigators were allowed to introduce MMFMMF. Only 0.8% of patients0.8\%\,\text{of patients} added MMFMMF during the study.

  • Autoimmune Subgroups: The trial was designed to reflect real-world practice, containing a significant chunk of ILD patients with autoimmune components:

    • Rheumatoid Arthritis (RARA): 10%10\%.

    • Systemic Sclerosis (SScSSc): 6%6\%.

    • Mixed Connective Tissue Disease (MCTDMCTD): 4%4\%.

    • Other autoimmune conditions: 7%7\%.

Primary Efficacy Results: Forced Vital Capacity (FVC)

  • Overall Population Findings (18 mg18\,mg dose):

    • The JASCADE 18 mg18\,mg group (with or without background anti-fibrotics) demonstrated a 43% relative reduction43\%\,\text{relative reduction} in FVCFVC decline

    • compared to the placebo group.

    • Placebo group decline: −152 ml-152\,ml.

    • JASCADE 18 mg18\,mg group: Significantly reduced decline compared to the −152 ml-152\,ml baseline.

  • Autoimmune ILD Subgroup:

    • Demonstrated a 39% relative reduction39\%\,\text{relative reduction} in FVCFVC decline.

    • Placebo group lost 100 ml100\,ml.

    • JASCADE group lost 62 ml62\,ml.

  • JASCADE Monotherapy Data (No background OFEVOFEV):

    • Placebo alone: −136 ml-136\,ml decline.

    • JASCADE 18 mg18\,mg alone: −83 ml-83\,ml decline.

    • Result: A 39% relative reduction39\%\,\text{relative reduction} in FVCFVC decline using JASCADE as a standalone treatment.

  • Timeline of Separation: Meaningful separation between the treatment and placebo lines began as early as week 2week\,2 and was maintained throughout the full 52 weeks52\,weeks.

Secondary Endpoints andSurvival Data

  • Composite Endpoint Performance: JASCADE did not meet statistical significance for the secondary composite endpoint (hospitalization, death, and exacerbations). However, for all three parameters, the data favored JASCADE (visualized on a forest plot).

  • Mortality and Number Needed to Treat (NNTNNT):

    • The trial followed patients beyond the primary period: the blinded trial up to 109 weeks109\,weeks and the end-of-trial up to 114 weeks114\,weeks.

    • Overall Population: The NNTNNT to prevent one death was 1313.

    • Autoimmune ILD Subgroup: The NNTNNT to prevent one death was 1111.

    • Exploratory Status: These findings are exploratory and were not adjusted for multiplicity, but they suggest a significant survival benefit.

Safety Profile and Tolerability

  • Diarrhea Incidence:

    • Overall (with background anti-fibrotics): 37%37\%.

    • JASCADE 18 mg18\,mg (without background anti-fibrotics): 27%27\%.

    • Placebo (without background): 16%16\%.

  • Discontinuation Rates due to Diarrhea:

    • JASCADE 18 mg18\,mg (no background): 0% to  1%0\%\,\text{to}\;1\%.

    • JASCADE + OFEVOFEV background: 4%4\%.

    • The low discontinuation rate suggests that while diarrhea occurs, it is generally manageable and not severe enough for most patients to quit the trial.

  • Prescribing Advantages:

    • No Contraindications: There are no listed warnings, precautions, or contraindications in the current labeling.

    • No Lab Monitoring: Unlike many other ILD treatments, JASCADE does not require routine liver function monitoring or other laboratory tests.

Dosing and Administration

  • Standard Dose: 18 mg18\,mg taken twice daily (BIDBID), approximately 12 hours12\,hours apart.

  • Food: Can be taken with or without food.

  • Dose Reduction: If a patient is unable to tolerate 18 mg18\,mg, the dose can be reduced to 9 mg9\,mg.

  • Special Instructions for Swallowing: Tablets can be taken whole or dispersed in water for patients with difficulty swallowing.

  • Drug-Drug Interactions: Clinical focus is on the lack of standard monitoring needed, though specifically mentioned was that pirfenidone only has an IPFIPF indication, not the broader PPFPPF (Progressive Pulmonary Fibrosis) indication.

Questions & Discussion

  • Question (Chris): The discontinuation rate for diarrhea seems very low (0−1%0-1\%) despite the reported adverse reaction rate. How do we explain this gap?

  • Response (Amy): Discontinuation usually happens in the first few months if at all. Patients in clinical trials are highly motivated as they are seeking the first new treatment in a decade. In the real world, motivation might be lower if they hear about side effects on social media, but for the study, the low dropout rate reflects that the symptom was manageable or the hope for treatment outweighed the discomfort.

  • Comment (Chris): Highlighting the lack of warnings, precautions, and liver monitoring is a huge selling point for providers compared to products like OFEVOFEV.

  • Response (Amy): This makes the prescribing process much more comfortable and less burdensome for both the doctor and the patient.

  • Question (Robin): Is there a line chart specifically for the monotherapy (18 mg18\,mg without background therapy) efficacy data?

  • Response (Amy): Currently, the data for monotherapy is presented in several ways but might not appear as a separate line chart in this specific deck version (compared to the IPFIPF deck). It shows a 39% relative reduction39\%\,\text{relative reduction} in FVCFVC decline.

  • Question (Attendee): How specific is the PDE4BPDE4B inhibition?

  • Response (Amy): It is 99-fold specific to the BB isoenzyme and does not touch AA, CC, or DD isoenzymes. This specificity is why we see fewer systemic side effects and why it works effectively in the lung interstitium where fibrosis and inflammatory problems occur.

  • Question (Attendee): Should we call it "CAMPCAMP" or spell out "C−A−M−PC-A-M-P"?

  • Response (Amy): It is fine to say "CAMPCAMP" as in a summer camp, but it is better to spell it out or define as Cyclic Adenosine Monophosphate at the start, as some providers may not have this specific pathway on their radar if they don't treat ILD frequently.